The first nutritional supplement against TB launches in Asia and Africa

Nyaditum resae targets to reduce the risk of developing the disease in people who carry the tuberculosis bacteria and those at risk of infection.

Under the agreement signed with Manremyc, Reig Jofre will lead the development and marketing phases in Europe, including the incorporation of Nyaditum resae as novel food in the European Food Safety Agency (EFSA), as well as its production at Reig Jofre’s facilities.

During CPHI Worldwide held earlier this week in Barcelona, Manremyc signed an agreement with the pharmaceutical group SRS Life Sciences based in Singapore and with presence in 77 countries, to market Nyaditum resae in sixteen countries of Asia and Africa.

This nutritional supplement, the result of more than 15 years of research led by Dr Pere-Joan Cardona at IGTP, targets to reduce the risk of developing the disease in both people who carry the tuberculosis bacteria and those at risk of infection.

According to Dr Cardona, CEO of Manremyc and director of the Experimental Tuberculosis Unit of IGTP: "TB affects disadvantaged populations without access to certain medications. Nyaditum resae intends to alleviate this situation by reaching more than 5 million people at an affordable price through this agreement." In this regard, Manremyc's project has been awarded the certificate B-Corp granted to companies with high social impact.